Rituximab in the treatment of refractory scleritis in patients with granulomatosis with polyangiitis (Wegener’s)

Purpose The purpose of this descriptive study was to evaluate the clinical response to rituximab (RTX) in patients with scleritis due to granulomatosis with polyangiitis (GPA), in patients who had proved refractory to treatment with systemic glucocorticoids and immunosuppressive agents.